| Name | Title | Contact Details |
|---|
Learn about how Johnson & Johnson Vision is committed to addressing the world-wide problems of vision impairment through prevention and treatment.
Mirum Pharmaceuticals (NASDAQ: MIRM) is dedicated to creating life-changing therapies for patients with liver diseases. We are advancing our lead product candidate for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) — conditions with a profound and devastating impact on quality of life for young patients and their families. Untreated, these conditions can lead to liver failure and inflict life-altering symptoms including stunted growth and severe, non-stop itching. Under current standard of care, patients often require a liver transplant and are at higher risk of many serious health issues. Working closely with patients and caregiver communities, we intimately understand the challenges of living with cholestatic liver diseases. Based on a wealth of data from clinical trials spanning multiple years and involving more than one hundred patients, we believe our approach can address the underlying cause of symptoms and liver damage. Our goal is to give families their lives back.
SOL-MILLENNIUM is a vertically integrated global medical supply company with locations across the globe. We are one of the worlds largest manufacturers of needles, syringes, and blood collection devices with a comprehensive line of medical supplies fo...
Scientia Vascular offers access devices (microcatheters / guidewires) and therapies that are optimized to address the evolving needs of interventional specialists. Learn more about our next-generation solutions.
Context Therapeutics Inc. (Nasdaq: CNTX) is a women`s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company`s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women`s cancers.